Stock Ratings / Health Care / APUS / dividends

XBIO (47) ADXN (57) CANF (31) PULM (36) ⌘ Pro Terminal →

Apimeds Pharmaceuticals US Inc. (APUS) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.21 +4.56% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.23

Apimeds Pharmaceuticals US Inc. (APUS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.23 (+0.63%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APUS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY APUS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$5.02-19.5% Next Q

Q2 (-2Q)

Grade D$4.04-28.5% Next Q

Q3 (-1Q)

Grade D$2.89+11.1% Next Q

Current

Grade D-$3.21-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APUS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APUS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.70) and Max Pain ($3.37) forces dealer call-delta covering toward $62.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APUS)

✓Walkthrough of APUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.93%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.11H $3.21L $2.84C $3.21VOL 21.5K

RES: $12.18SUP: $-1.13SMA50: $3.70SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APUS Butterfly Map → + Track APUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APUS)

Health Care Rank #563 of 1016 ⚔️ XBIO vs APUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APUS vs. XBIO, ADXN, CANF, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apimeds Pharmaceuticals US Inc. (APUS) ranks #563 by composite RQD confidence (43/100, grade D-) and #949 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, APUS leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with APUS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APUS ACTIVE Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	Benchmark Subject
XBIO Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-apus →
ADXN Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	/adxn-vs-apus →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-apus →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-apus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894525

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$6.0M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-1124.6% YoY). On the balance sheet, APUS closed FY2025 with $164.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$6.0M	-$8.9M	-$9.0M	$164.2M	—
FY2024 (FY)	2024-12-31	$0	-$1.4M	-$733.5K	-$733.5K	$13.1K	—
FY2023 (FY)	2023-12-31	$0	-$777.7K	-$627.8K	-$627.8K	—	—

3. APUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.21 (+4.56% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APUS ranks #563 in composite RQD confidence.

How does APUS compare to XBIO and ADXN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.2%. By comparison, XBIO (Xenetic Biosciences Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M) and ADXN (Addex Therapeutics Ltd) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APUS?

Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $0 in revenue, -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APUS trading relative to its 50-day, 200-day, and 52-week technical levels?

APUS last traded at $3.21 (+4.56% on volume of 50,074 shares), positioning the stock -13.24% below its 50-day simple moving average ($3.70) and -70.55% below its 200-day simple moving average ($10.90). Across its 52-week range of $1.51 to $59.70, APUS sits at the 2.9% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.81 to $3.61).

APUS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does APUS pay a dividend and is it safe?

Apimeds Pharmaceuticals US Inc. (APUS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: APUS RQD Cockpit APUS 12M Forecast APUS Earnings & Move APUS Dividends & DRIP APUS Insiders & 13F APUS Whale Options APUS Profit Sankey APUS News & Why